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sequitur for your editorial commentary on these trials convolutedly
to conclude that many patients receiving long-term ACE inhibi-
tors should be denied the proven benefits of long-term aspirin
therapy in exchange for the less clearly proven benefits of other
antiplatelet agents.
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REPLY
Thank you for your comments. At issue is not primarily the
long-term effects of aspirin in coronary artery disease but its
combination with an angiotensin-converting enzyme (ACE) in-
hibitor in patients with heart failure (1). Any real benefits of
long-term aspirin therapy, however, have been regarded, at best, as
questionable. The meta-analysis (1) on which your argument is
based is characterized by important weaknesses and shortcomings
which Dr. Cleland has done a good job of pointing out (2).
I am sure that no responsible physician wants to deny patients
drugs of proven benefit. However, the negation of an interaction (3)
based on results of the use of otherwise effective heart failure drugs
which, in 90,000 patients taking the combination of an ACE
inhibitor with aspirin, did conspicuously little or nothing is a
benefit with which some physicians are not content. There was not
even prevention of heart failure. Moreover, in the most recent
meta-analysis cited (4) in your letter in which, similar to that of
Latini et al. (3), the patient groups are dissimilar, there was a
consistently more favorable risk reduction in patients without
aspirin (0.85 vs. 0.75 and 0.76 vs. 0.68 for death and combined
death, heart failure and myocardial infarction in the aspirin vs. no
aspirin groups, respectively). Consequently, in consideration of the
comparative yield of the combination of an ACE inhibitor and
aspirin and an ACE inhibitor without aspirin (Table 1 of reference
[5]), it appears, rather, that with the combination, we are denying
many patients an effective treatment for heart failure.
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Papillary Muscle Hypothesis of
Idiopathic Left Ventricular Tachycardia
Nogami et al. (1) recently demonstrated that diastolic (P1) and
presystolic (P2) Purkinje potentials are critical potentials in a
macroreentry circuit of verapamil-sensitive idiopathic left ventric-
ular tachycardia. The authors posit that P1 represents the activa-
tion potential in the distal portion of the specialized Purkinje tissue
and P2 represents the activation potential of the left posterior
fascicle. There was no mentioning of the papillary muscle as a
possible source of these potentials.
In most parts of the ventricular endocardium, Purkinje poten-
tials and myocardial potentials are nonseparable. This is not true at
the papillary muscle, where Purkinje potentials and ventricular
muscle potentials are widely separated (2,3). Joyner et al. (2)
reported that pacing from a Purkinje strand inserting into the apex
of the papillary muscle results in apex to base Purkinje activation.
The activation then excites the ventricular muscle via the Purkinje
ventricular muscle junction at the base of the papillary muscle, and
propagates from base of the papillary muscle to the apex of the
papillary muscle. The resulting activation sequence shown in
Figure 1B of that article is identical to the sequence of activation
shown in Figure 2 of the study of Nogami et al. (1). The Purkinje
strands (fibromuscular band or false tendon), which are often seen
in dogs, are also found commonly in humans, especially among
patients with idiopathic left ventricular tachycardia (4).
The safety factor of propagation from Purkinje to ventricular
muscle is lower than that from the ventricular muscle to the
Purkinje fibers (2,5). This asymmetrical safety factor of propaga-
tion may contribute to the occurrence of unidirectional block and
reentry. The papillary muscle may serve as an anchor to reentrant
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wavefronts (3), resulting in sustained ventricular tachycardia.
These two mechanisms may be important in the generation and
maintenance of sustained ventricular tachycardia near the papillary
muscle.
Clearly separated Purkinje potentials are characteristic findings
for endocardial recordings near the papillary muscle (2,3). Success-
ful radiofrequency ablation at these sites (1) suggests that the
reentrant wavefronts responsible for idiopathic left ventricular
tachycardia are adjacent to or are located within the papillary
muscle.
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REPLY
We are grateful for the opportunity to respond to the comments by
Dr. Chen et al. concerning our recent article in the Journal (1). I
was very impressed by the study of Joyner et al. (2), that reported
on longitudinal dissociation of ventricular muscle and Purkinje
signals in isolated papillary muscle of a dog. According to Figure
1B in their article, pacing from a Purkinje strand inserting into the
apex of the papillary muscle resulted in apex to base Purkinje
activation, which then excited the ventricular muscle via the
Purkinje-muscle junction at the base of the papillary muscle with
propagation of the excitation from the base to apex of the papillary
muscle. Their Figure 1B is similar to our Figure 2A, as Dr. Chen
et al. have suggested. According to the results of Joyner et al. (2),
our diastolic potential (P1) appeared to be the result of a signal
from the local ventricular muscle of the papillary muscle, and our
presystolic potential (P2) that from the local Purkinje activation of
the papillary muscle. However, there are several differences be-
tween our study and the study by Joyner et al. First, while the
Purkinje-muscle junction in their study was located at the base of
the papillary muscle, the Purkinje-muscle transmission occurred at
the infero-apical septum in our study. The position of the
octapolar electrode catheter shown in our Figure 1 differed from
the site of the posterior papillary muscle. The activation sequences
of the Purkinje potential during sinus rhythm may also differ.
Because Purkinje fibers enter the anterior and posterior papillary
muscles through the trabeculae carneae, the activation sequence of
the Purkinje potential in the papillary muscle during sinus rhythm
must be from the apex to the base. However, our P2 was recorded
earlier from the proximal than the distal electrodes during sinus
rhythm. We think that P1 is the potential from the trabeculae
carneae. Trabeculae carneae form ridges, bridges and small papil-
lary muscles. Lai et al. (3) proposed a false tendon or interlacing
Purkinje fiber as a link between the slow conduction tissue and left
posterior fascicle. Gallagher et al. (4) and Thakur et al. (5) have
also implied that the left ventricular muscular band may be the
anatomic substrate for idiopathic left ventricular tachycardia.
However, Lin et al. (6) have shown that the left ventricular
muscular band is not the specific arrhythmogenic substrate for this
tachycardia. However, trabeculae carneae or small papillary mus-
cles cannot be detected by echocardiography. Nevertheless, longi-
tudinal dissociation of the ventricular muscle and Purkinje signals
from the papillary muscle and trabeculae carneae, and the presence
of the Purkinje-muscle junction, are important in considering the
reentry circuit of verapamil-sensitive idiopathic left ventricular
tachycardia.
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The Enigma of Primary
Pulmonary Hypertension
Riley et al. (1) observed that exercise increased heart rates and
decreased oxygen saturations of arterial hemoglobin abnormally in
patients who had primary pulmonary hypertension. They stated
that this occurs in subjects with circulatory disease or decondition-
ing. They did not refer to the studies showing that fast heart rates
and desaturation of arterial hemoglobin also occur in well-trained
athletes (2,3). They did not measure cardiac outputs in their
patients to allow them to calculate stroke volumes, but they
concluded that low stroke volume, resulting from pulmonary
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